Frankreich

RUBIS: Availability of the 2020 half-year financial report

Thursday, September 17, 2020 - 5:05pm

This document is a translation of the original French document and is provided for information purposes only.

Key Points: 
  • This document is a translation of the original French document and is provided for information purposes only.
  • In all matters of interpretation of information, views or opinions expressed therein, the original French version takes precedence over this translation.
  • Rubis announced today that its 2020 half-year financial report as of June 30, 2020 is available.
  • This report has been filed with the French Financial Markets Authority (AMF).

RUBIS: Great resilience in the face of Covid - EBITDA: down 11% - Net income: down 11%

Thursday, September 17, 2020 - 5:04pm

Of the 44 million like-for-like drop in the gross distribution margin in Q2, 97% is attributable to the fall in volumes.

Key Points: 
  • Of the 44 million like-for-like drop in the gross distribution margin in Q2, 97% is attributable to the fall in volumes.
  • The worst impact was felt in the area of white goods, and notably aviation, where the sharp drop in sales did not allow for normal inventory turnover.
  • The results of the SARA refinery are governed by the application of a decree setting profitability at 9% of shareholders' equity.
  • After refinancing, the net income (Group share) of the Rubis Terminal JV totalled 11 million, down 12%.

RUBIS: 2020 Half-year financial report

Thursday, September 17, 2020 - 5:04pm

Dissemination of a French Regulatory News, transmitted by EQS Group.

Key Points: 

Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

DGAP-News: Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

Thursday, September 17, 2020 - 7:02am

PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.

Key Points: 
  • PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.
  • Founded in February 2020, Gradient Denervation Technologies ("Gradient") builds on an innovation from two clinicians from Stanford University, Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein.
  • Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology developed by two clinicians from Stanford University.
  • It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.